Trial design
The single study employed a prospective randomized controlled clinical trial with three arms parallel group with 1:1:1 allocation ratio. The study design was approved by the Research Ethical Board in Gothenburg, Sweden (Reg. no. 321-09). The study protocol was not registered. No changes were made to the methods after trial commencement.